2023 World Conference on Lung Cancer (Posters)-P2.08. A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model

P2.08. A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model - PDF(Slides)

Back to course

Pdf Summary

This document outlines a Phase II study being conducted on subcutaneous (SC) atezolizumab, a monoclonal antibody, for the treatment of non-small cell lung cancer (NSCLC). The study aims to evaluate the feasibility and effectiveness of using a decentralized clinical trial model, which allows patients to receive treatment at home instead of in the clinic. This approach has become increasingly important due to the disruptions in patient care caused by the Covid-19 pandemic.<br /><br />The use of subcutaneous administration of monoclonal antibodies, like atezolizumab, is a strategy for promoting remote cancer care. It is a safe and effective alternative to intravenous delivery and offers convenience and cost-effectiveness for patients. The study will use the same fixed dose of 1875mg that was used in a previous trial.<br /><br />Remote patient monitoring is now possible with the use of consumer-grade technologies. Oncologists can implement digital monitoring strategies, such as wearable devices and electronic patient-reported outcome metrics, to replace traditional physical examinations. This allows oncologists to collect data points about a patient's disease status between visits, leading to a more specific and data-driven approach to oncology care.<br /><br />The study will enroll NSCLC patients who are eligible for atezolizumab treatment for approved indications. These indications include locally advanced or metastatic patients with high PD-L1 expression, patients with disease progression during or following platinum-containing chemotherapy, and patients who have undergone resection and platinum-based chemotherapy for stage II to IIIA NSCLC.<br /><br />The study is being conducted in collaboration with Cansera, and funding is provided by Genentech. The study schema involves a total of 37 patients.<br /><br />Overall, this study aims to evaluate the feasibility and effectiveness of using subcutaneous atezolizumab in NSCLC patients using a decentralized clinical trial model. The use of digital monitoring strategies will provide valuable data for evaluating patient outcomes and the efficacy of the treatment.

Asset Subtitle

Jorge Nieva

Meta Tag

Speaker Jorge Nieva

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

Phase II study

subcutaneous atezolizumab

monoclonal antibody

non-small cell lung cancer

NSCLC

decentralized clinical trial model

remote cancer care

subcutaneous administration

digital monitoring strategies

patient outcomes